Effectiveness of a personal health coaching intervention (diabetescoach) in patients with type 2 diabetes: protocol for an open-label, pragmatic randomised controlled trial

被引:3
|
作者
Hohberg, Vivien [1 ]
Kreppke, Jan-Niklas [1 ]
Kohl, Jan [2 ]
Seelig, Eleonora [3 ,4 ]
Zahner, Lukas [1 ]
Streckmann, Fiona [1 ,5 ]
Gerber, Markus [1 ]
Konig, Daniel [2 ,6 ]
Faude, Oliver [1 ]
机构
[1] Univ Basel, Dept Sport Exercise & Hlth, Basel, Switzerland
[2] Univ Freiburg, Inst Sports & Sport Sci, Freiburg, Germany
[3] Univ Hosp Basel, Endocrinol Diabetol & Metab, Basel, Switzerland
[4] Cantonal Hosp Basel Landschaft, Endocrinol & Diabetol, Vestal, Switzerland
[5] Univ Hosp Basel, Onkol, Basel, Switzerland
[6] Univ Vienna, Inst Nutr Exercise & Hlth, Vienna, Austria
来源
BMJ OPEN | 2022年 / 12卷 / 06期
关键词
LIPOPROTEIN INSULIN-RESISTANCE; LIFE-STYLE INTERVENTION; PHYSICAL-ACTIVITY; POSITION STATEMENT; METABOLIC SYNDROME; SELF-EFFICACY; OBESE ADULTS; EXERCISE; BEHAVIOR; RISK;
D O I
10.1136/bmjopen-2021-057948
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction The widespread prevalence of type 2 diabetes (T2D) not only influences patients' daily lives but also has an economic impact on society. Increasing physical activity and a healthy diet can delay the progression of T2D. Although there are evidence-based recommendations on diet and physical activity, patients with T2D have difficulties implementing them. An appropriate lifestyle intervention can address this problem. Methods and analysis This study is based on the need to develop an intervention that helps patients to establish behavioural changes in order to achieve glycaemic control. The intervention will be evaluated in a monocentric, open-label, pragmatic, two-arm randomised controlled trial with a sample ratio of 1:1 and a parallel design. This superiority study will be conducted in Switzerland. All enrolled patients (n=90) will receive the standard medical treatment for T2D. The intervention group will receive personal health coaching by telephone and access to a smartphone and web application for 1 year. The control group will receive access to the application for 1 year and a one-time written diet and exercise recommendation. The primary outcomes are objectively measured physical activity and glycated haemoglobin. Secondary outcomes are self-reported physical activity, nutrition, cognitive mediators of changes in sport-related behaviour, blood values, medication and nutritional supplements, anthropometric data, quality of life, neuropathy and cost-effectiveness. All outcomes will be measured at baseline, at 27 weeks after inclusion and at 54 weeks after inclusion. The recruitment of participants and the measurements will be completed after 2 years. Linear mixed-effects models will be applied for each outcome variable to analyse the intervention effects. Ethics and dissemination This study was approved by the Ethics Committee North-western and Central Switzerland in February 2021 (ref: 2020-02755). All participants will be required to provide written informed consent. The results will be published in international peer-reviewed journals.
引用
下载
收藏
页数:15
相关论文
共 50 条
  • [31] Physical activity coaching for adults with mobility limitations: protocol for the ComeBACK pragmatic hybrid effectiveness-implementation type 1 randomised controlled trial
    Hassett, Leanne
    Tiedemann, Anne
    Hinman, Rana S.
    Crotty, Maria
    Hoffmann, Tammy
    Harvey, Lisa
    Taylor, Nicholas F.
    Greaves, Colin
    Treacy, Daniel
    Jennings, Matthew
    Milat, Andrew
    Bennell, Kim L.
    Howard, Kirsten
    van den Berg, Maayken
    Pinheiro, Marina
    Wong, Siobhan
    Kirkham, Catherine
    Ramsay, Elizabeth
    O'Rourke, Sandra
    Sherrington, Catherine
    BMJ OPEN, 2020, 10 (11):
  • [32] Immunogenicity and safety of hepatitis B vaccination in patients with type 2 diabetes in China: An open-label randomized controlled trial
    Han, Bingfeng
    Liu, Wu
    Du, Juan
    Liu, Hanyu
    Zhao, Tianshuo
    Yang, Shubo
    Wang, Shuai
    Zhang, Sihui
    Liu, Bei
    Liu, Yaqiong
    Cui, Fuqiang
    VACCINE, 2021, 39 (25) : 3365 - 3371
  • [33] A tailored, interactive health communication application for patients with type 2 diabetes: study protocol of a randomised controlled trial
    Nina Weymann
    Martin Härter
    Jörg Dirmaier
    BMC Medical Informatics and Decision Making, 13
  • [34] Visualization of asymptomatic atherosclerotic disease for optimum cardiovascular prevention (VIPVIZA): a pragmatic, open-label, randomised controlled trial
    Naslund, Ulf
    Ng, Nawi
    Lundgren, Anna
    Fharm, Eva
    Gronlund, Christer
    Johansson, Helene
    Lindahl, Bernt
    Lindahl, Bertil
    Lindvall, Kristina
    Nilsson, Stefan K.
    Nordin, Maria
    Nordin, Steven
    Nyman, Emma
    Rocklov, Joacim
    Vanoli, Davide
    Weinehall, Lars
    Wennberg, Patrik
    Wester, Per
    Norberg, Margareta
    LANCET, 2019, 393 (10167): : 133 - 142
  • [35] A tailored, interactive health communication application for patients with type 2 diabetes: study protocol of a randomised controlled trial
    Weymann, Nina
    Haerter, Martin
    Dirmaier, Joerg
    BMC MEDICAL INFORMATICS AND DECISION MAKING, 2013, 13
  • [36] The effectiveness, reproducibility, and durability of tailored mobile coaching on diabetes management in policyholders: A randomized, controlled, open-label study
    Lee, Da Young
    Park, Jeongwoon
    Choi, Dooah
    Ahn, Hong-Yup
    Park, Sung-Woo
    Park, Cheol-Young
    SCIENTIFIC REPORTS, 2018, 8
  • [37] The effectiveness, reproducibility, and durability of tailored mobile coaching on diabetes management in policyholders: A randomized, controlled, open-label study
    Da Young Lee
    Jeongwoon Park
    Dooah Choi
    Hong-Yup Ahn
    Sung-Woo Park
    Cheol-Young Park
    Scientific Reports, 8
  • [38] Assessing the efficacy and impact of a personalised smoking cessation intervention among type 2 diabetic smokers: study protocol for an open-label randomised controlled trial (DISCGO-RCT)
    Clair, Carole
    Augsburger, Aurelie
    Birrer, Priska
    Locatelli, Isabella
    Schwarz, Joelle
    Greub, Gilbert
    Zanchi, Anne
    Jacot-Sadowski, Isabelle
    Puder, Jardena J.
    BMJ OPEN, 2020, 10 (11):
  • [39] Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial
    Gallwitz, Baptist
    Guzman, Juan
    Dotta, Francesco
    Guerci, Bruno
    Simo, Rafael
    Basson, Bruce R.
    Festa, Andreas
    Kiljanski, Jacek
    Sapin, Helene
    Trautmann, Michael
    Schernthaner, Guntram
    LANCET, 2012, 379 (9833): : 2270 - 2278
  • [40] Association between vitamin D and uterine fibroids: a study protocol of an open-label, randomised controlled trial
    Sheng, Bo
    Song, Yizuo
    Liu, Yi
    Jiang, Chenchen
    Zhu, Xueqiong
    BMJ OPEN, 2020, 10 (11):